ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors

Metastatic urothelial carcinoma is generally incurable with current systemic therapies. Chromatin modifiers are frequently mutated in bladder cancer, with ARID1A-inactivating mutations present in about 20% of tumors. EZH2, a histone methyltransferase, acts as an oncogene that functionally opposes AR...

Descripción completa

Detalles Bibliográficos
Autores principales: Rehman, Hasibur, Chandrashekar, Darshan S., Balabhadrapatruni, Chakravarthi, Nepal, Saroj, Balasubramanya, Sai Akshaya Hodigere, Shelton, Abigail K., Skinner, Kasey R., Ma, Ai-Hong, Rao, Ting, Agarwal, Sumit, Eich, Marie-Lisa, Robinson, Alyncia D., Naik, Gurudatta, Manne, Upender, Netto, George J., Miller, C. Ryan, Pan, Chong-xian, Sonpavde, Guru, Varambally, Sooryanarayana, Ferguson, James E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462490/
https://www.ncbi.nlm.nih.gov/pubmed/35852858
http://dx.doi.org/10.1172/jci.insight.155899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462490/
https://www.ncbi.nlm.nih.gov/pubmed/35852858
http://dx.doi.org/10.1172/jci.insight.155899

Ejemplares similares